Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21437041 | 1.00 | MEN1 (0.41) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL21738201 | 0.91 | MEN1 (0.42) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL6507456 | 0.90 | MEN1 (0.45) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL11726714 | 0.90 | MEN1 (0.45) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL12758959 | 0.90 | MEN1 (0.41) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL28786679 | 0.89 | MEN1 (0.47) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL11280223 | 0.89 | MEN1 (0.47) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL13306435 | 0.83 | MEN1 (0.38) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL21437122 | 0.83 | MEN1 (0.37) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL9195356 | 0.83 | MEN1 (0.40) | MEN1KMT2AKDM4CL3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260041671-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-12539292-B2 | BRM targeting compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| EP-4633734-A1 | COMPOUNDS, COMPOSITIONS, AND MEZHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN MISFOLDING | Wavebreak Therapeutics, LLC (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-4537905-A2 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-3774789-B1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS INC (US) | 2025-03-05 | — | — | EP | disclosed |
| WO-2024129881-A1 | COMPOUNDS, COMPOSITIONS, AND MEZHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN MISFOLDING | WAVEBREAK THERAPEUTICS LIMITED (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20240076295-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | GENENTECH, INC. | 2024-03-07 | — | — | US | disclosed |
| EP-4038066-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2022-08-10 | — | — | EP | disclosed |
| CN-114787159-A | BRM targeting compounds and related methods of use | 阿尔维纳斯运营股份有限公司 | 2022-07-22 | — | — | CN | disclosed |
| WO-2021067606-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| US-20030008849-A1 | Acetylenic alpha -amino acid-based sulfonamide hydroxamic acid tace inhibitors | LEVIN JEREMY I (US) | 2003-01-09 | — | — | US | disclosed |
| US-20020151734-A1 | 12-HETrE analogs and methods of use thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2002-10-17 | — | — | US | disclosed |
| WO-2002076395-A2 | AGENTS AND METHODS FOR TREATMENT OF CANCER | PHARMACIA CORPORATION (US) | 2002-10-03 | — | — | WO | disclosed |
| US-20020132849-A1 | 2-Amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors | PHARMACIA LLC | 2002-09-19 | — | — | US | disclosed |
| WO-2002059072-A2 | 12-HYDROXY-EICOSATRIENOIC ACID ANALOGS AND METHODS OF USE THEREOF | NEW YORK MEDICAL COLLEGE (US) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002022562-A1 | 2-AMINO-2-ALKYL-5 HEPTENOIC AND HEPTYNOIC ACID DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | PHARMACIA CORPORATION (US) | 2002-03-21 | — | — | WO | disclosed |
| EP-1144368-A2 | ACETYLENIC ALPHA-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS | American Cyanamid Company (US) | 2001-10-17 | — | — | EP | disclosed |
| US-6225311-B1 | Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors | AMERICAN CYANAMID COMPANY | 2001-05-01 | — | — | US | disclosed |
| WO-2000044709-A2 | ACETYLENIC α-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
| US-4560551-A | 12-METHYLOXACYCLODODEC-4-EN-2-ONE, 12-METHYLOXACYCLODODECA-4,7-DIEN-2-ONE, HEXANAL, OCTANAL, NONANAL | PIERCE ALDONA M | 1985-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008849-A1 | Acetylenic alpha -amino acid-based sulfonamide hydroxamic acid tace inhibitors | TNF, SI, TASP1 | MEN1 2930/4885KMT2A 2103/4885KDM4C 4342/4885 |
| US-20240076295-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ADRM1, BRAP, VHL | MEN1 2768/4885KMT2A 874/4885KDM4C 2685/4885 |
| US-12539292-B2 | BRM targeting compounds and associated methods of use | ADRM1, SUMO2, BAZ1A | MEN1 3886/4885KMT2A 1067/4885KDM4C 2478/4885 |
| US-20020151734-A1 | 12-HETrE analogs and methods of use thereof | PTGIR, ALOX5, ALOX15B | MEN1 2193/4885KMT2A 3278/4885KDM4C 2465/4885 |
| US-20260041671-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ADRM1, VHL, BAZ1A | MEN1 4186/4885KMT2A 928/4885KDM4C 2197/4885 |
| US-20020132849-A1 | 2-Amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors | PTGIS, ALOX5, ALOX15 | MEN1 4444/4885KMT2A 1869/4885KDM4C 2822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.